DJDiogo Jesus

Diogo Jesus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Diogo Jesus has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ability of SLE-DAS and SLEDAI-2K to predict damage accrual in SLE: a real-world 7-year cohort study from Sweden

    by Rama Andraos, Alexander Tsoi, Alf Kastbom, Martina Frodlund, Diogo Jesus, Luís Sousa Inês, Ioannis Parodis, Christopher Sjöwall

    Objectives: SLE remains a heterogeneous autoimmune disease that can lead to irreversible organ damage. SLE Disease Activity Score (SLE-DAS) is a recently developed tool with higher sensitivity to change than SLE Disease Activity Index-2000 (SLEDAI-2K). We compared SLE-DAS with other activity measures in terms of ability to predict organ damage. Methods: Patients from Linköping University Hospital with ≥2 visits between 2008 and 2025 were included. SLEDAI-2K and Physician’s Global Assessment (PhGA) were assessed prospectively, and SLE-DAS retrospectively. Organ damage was estimated annually using the SLICC/ACR Damage Index (SDI). Adjusted mean scores of SLEDAI-2K (amSLEDAI-2K), PhGA (amPhGA) and SLE-DAS (amSLE-DAS) were determined for each time interval between consecutive visits, and their ability to predict damage accrual was evaluated using time-dependent multivariable Cox regression models. Predictive ability was compared across measures using Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). Results: In total, 335 patients with 3582 outpatient visits contributed data. amSLE-DAS was an independent predictor of SDI increase at the 3- (HR; 95% CI: 1.04; 1.00–1.08), 5- (1.05; 1.01–1.09) and 7-year follow-up (1.04; 1.00–1.08). amSLEDAI-2K was predictive at the 5-year follow-up only (1.12; 1.02–1.22), and amPhGA at 5 (1.99; 1.19–3.36) and 7 (1.84; 1.02–3.30) years. amSLE-DAS showed a higher predictive ability for damage accrual than amSLEDAI-2K at the 3-, 5- and 7-year follow-up, as indicated by lower AIC and BIC. Conclusion: In this real-world Swedish setting, we demonstrate that SLE-DAS outperforms SLEDAI-2K in predicting organ damage accrual in SLE, substantiating its clinical relevance.

  • SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2–3 trials

    by Diogo Jesus, Carla Henriques, Ana Matos, Andrea Doria, Luís Sousa Inês

    Objectives: The objectives of this study were to develop and evaluate the performance of the novel SLE-DAS Responder Index (RI) as an efficacy end point in SLE trials, and to assess the utility of SLE-DAS in identifying moderate-to-severe disease activity (MSDA). Methods: This post-hoc analysis pooled data from the placebo arms of three randomized controlled trials of anifrolumab (MUSE, TULIP-1, and TULIP-2). The SLE-DAS RI was defined as a reduction in SLE-DAS of ≥1.72 and a score of ≤7.64 at week 52. Associations between SLE-DAS RI and changes in disease activity, glucocorticoid exposure, and health-related quality of life (HR-QoL) were evaluated using regression models. The predictive performance of SLE-DAS RI for HR-QoL was compared with the BILAG-based Composite Lupus Assessment (BICLA) and the SLE Responder Index (SRI-4). Flare occurrence was analysed using the SLE-DAS flare tool and Cox regression. The ability of SLE-DAS to identify MSDA was assessed at screening and week 12, using BILAG-2004 and SLEDAI-2K as comparators. Results: Of 438 patients, 34.0% achieved SLE-DAS RI response at week 52. Responders showed greater reductions in disease activity, lower cumulative glucocorticoid exposure, and significantly improved HR-QoL. Multiple linear regression identified SLE-DAS RI response as the most significant predictor of HR-QoL improvements across multiple domains. SLE-DAS RI responders had 41.9% lower risk of flare. At screening, SLE-DAS MSDA identified 96.1% of patients with MSDA and better reflected HR-QoL burden at week 12. Conclusion: The SLE-DAS RI is a robust efficacy end point in SLE trials, associated with sustained disease control and meaningful improvements in patient-reported outcomes. SLE-DAS also enables accurate identification of MSDA, supporting its broader utility in trial design.


  • Open Access

    SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies

    by Diogo Jesus, Ana Matos, Carla Henriques, Andrea Doria, Luis Sousa Ines

    Objectives: This study aimed to derive and validate a cut-off for severe disease activity (SDA) using the SLE Disease Activity Score (SLE-DAS) and compare its accuracy and impact on health-related quality of life (HR-QoL) with the British Isles Lupus Assessment Group 2004 (BILAG-2004) and SLE Disease Activity Index 2000 (SLEDAI-2K). Methods: We performed a post hoc analysis of pooled placebo arm data from the MUSE (A Phase II, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus), TULIP-1 and TULIP-2 (Treatment of Uncontrolled Lupus via the Interferon Pathway) trials, including 438 patients with moderate-to-severe SLE. SLE-DAS was scored retrospectively, and a cut-off for SDA was derived using receiver operating characteristic (ROC) curves against the BILAG-2004 numerical score >11 as gold standard. Multiple linear regression analysis and Cohen’s d effect size were applied to evaluate the effectiveness of SLE-DAS, BILAG-2004 and SLEDAI-2K SDA classifications in capturing HR-QoL patient-reported outcomes (PROs). Results: The optimal SLE-DAS cut-off for SDA was >9.90 (area under the ROC curve=0.847, sensitivity=77.8%, specificity=79.6%). Patients classified as SDA by both SLE-DAS and BILAG-2004 or only by SLE-DAS exhibited similar disease activity, while those classified by BILAG-2004 alone had less severe disease and better HR-QoL. The SLE-DAS cut-off was associated with worse HR-QoL across multiple PROs more consistently than BILAG-2004 or SLEDAI-2K. Conclusion: The SLE-DAS cut-off for SDA provides an accurate definition of SDA in SLE, with good discriminative power and consistent associations with worse HR-QoL. This SLE-DAS definition enhances disease activity classification and offers a practical tool for guiding treatment decisions in clinical practice, as well as selecting patients with SDA for inclusion in clinical trials.


  • Relationship Between Ultrasound and Physical Examination in the Assessment of Enthesitis in Patients With Spondyloarthritis: Results From the DEUS Multicenter Study

    by Andrea Di Matteo, Stefano Di Donato, Gianluca Smerilli, Andrea Becciolini, Federica Camarda, Alberto Cauli, Tomás Cazenave, Edoardo Cipolletta, Davide Corradini, Juan Jose de Agustin, et al.

    Objective: The study objectives were (i) to explore the agreement between the Outcome Measures in Rheumatology (OMERACT) ultrasound lesions of enthesitis and physical examination in assessing enthesitis in patients with spondyloarthritis (SpA) and (ii) to investigate the prevalence and clinical relevance of subclinical enthesitis in this population.Methods: Twenty rheumatology centers participated in this cross‐sectional study. Patients with SpA, including axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), underwent both ultrasound scan and physical examination of large lower limb entheses. The OMERACT ultrasound lesions of enthesitis were considered, along with a recently proposed definition for “active enthesitis” by our group. Subclinical enthesitis was defined as the presence of “active enthesitis” in ≥1 enthesis in patients with SpA without clinical enthesitis (ie, number of positive entheses on physical examination and Leeds Enthesitis Index score = 0).Results: A total of 4,130 entheses in 413 patients with SpA (224 with axSpA and 189 with PsA) were evaluated through ultrasound and physical examination. Agreement between ultrasound and physical examination ranged from moderate (ie, enthesophytes) to almost perfect (ie, power Doppler and “active enthesitis”). Patellar tendon entheses demonstrated the highest agreement, whereas Achilles tendon insertion showed the lowest. Among 158 (38.3%) of 413 patients with SpA with clinical enthesitis, 108 (68.4%) exhibited no “active enthesitis” on ultrasound. Conversely, of those 255 without clinical enthesitis, 39 (15.3%) showed subclinical enthesitis. Subclinical enthesitis was strongly associated with local structural damage. However, no differences were observed regarding the demographic and clinical profiles of patients with SpA with and without subclinical enthesitis.Conclusion: Our study underscores the need for a comprehensive tool integrating ultrasound and physical examination for assessing enthesitis in patients with SpA. image


  • Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health‐Related Quality of Life

    by Diogo Jesus, Carla Henriques, Ana Matos, Andrea Doria, Luís S. Inês

    Objective: Our objective was to evaluate the ability of Systemic Lupus Erythematosus Disease Activity Score (SLE‐DAS) remission and low disease activity (LDA) to discriminate active drug from placebo and to discriminate outcomes in the patients’ perspective (health‐related quality of life [HR‐QoL]) in SLE trials.Methods: This was a post hoc analysis of the pooled Belimumab in Subjects With SLE (BLISS)‐52 (NCT00424476) and BLISS‐76 (NCT00410384) trials data. SLE‐DAS remission and LDA attainment and discrimination between belimumab and placebo at 52 weeks were compared using chi‐square tests. At week 52, 36‐item Short Form Health Survey (SF‐36) and Functional Assessment of Chronic Illness Therapy Fatigue (FACIT‐F) scores were compared between patients attaining SLE‐DAS remission versus nonremission and SLE‐DAS LDA versus non‐LDA using the t‐test and Mann‐Whitney test. Mean changes from week 0 to 52 in SF‐36 and FACIT‐F scores were compared between groups using multivariate regression analysis adjusted for baseline scores.Results: At week 52, significantly more patients attained SLE‐DAS LDA taking belimumab 1 mg/kg (17.9% vs 13.0%; P = 0.023; odds ratio [OR] 1.459; relative risk [RR] 1.377; number needed to treat [NNT] 20.4) and 10 mg/kg (21.7% vs 13.0%; P < 0.001; OR 1.853; RR 1.668; NNT 11.5) compared with placebo. Likewise, more patients attained SLE‐DAS remission taking belimumab 10 mg/kg compared to placebo (14.7% vs 10.1%; P = 0.019; OR 1.532; RR 1.454; NNT 21.7). At week 52, patients attaining SLE‐DAS remission and LDA presented higher SF‐36 domain and summary scores (all P < 0.001) and FACIT‐F scores (both P < 0.001). Mean improvements from baseline in SF‐36 and FACIT‐F scores were significantly higher in patients achieving SLE‐DAS remission and LDA.Conclusion: SLE‐DAS remission and LDA showed discriminant ability for identifying patients receiving active drug in SLE clinical trials. Attainment of these SLE‐DAS targets are associated with better HR‐QoL.


  • The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study

    by Liliana Saraiva, Rita N Cunha, Diogo Jesus, Mariele Gatto, Margherita Zen, Luca Iaccarino, José A P da Silva, Andrea Doria, Luís Sousa Inês

    Objective: To assess the criterion validity of the SLE disease activity score (SLE-DAS) flare tool and compare its performance in identifying flares against other instruments. Methods: Patients with SLE fulfilling SLE-DAS low disease activity at baseline were included from two academic lupus clinics. During follow-up, flares were identified by the senior attending clinician, applying the expert-consensus-based definition as gold-standard. The first clinical flare from flaring patients, and the first visit after baseline in patients without flares were analysed. In each no flare/flare visits, we assessed flares by SLE-DAS (score increase ≥1.72), classic-SELENA Flare Index (c-SELENA FI), revised-SELENA FI (r-SELENA FI), and SLEDAI-2K (score increase ≥4). We estimated the sensitivity, specificity, and Cohen’s Kappa agreement of each flare tool against the gold-standard. Results: A total of 442 patients were included and followed-up for 22.9 (14.2) months. Incidence of flares was 8.19/100 patient-years, with 69 patients experiencing flares. The SLE-DAS identified 96.6% of the expert-defined flares implying a treatment change and classified 28.0% of those as moderate/severe. Sensitivity and specificity for the gold-standard flare definition were: SLE-DAS 97.1% and 97.3%, c-SELENA FI 88.4% and 98.1%, r-SELENA FI 88.4% and 96.8%, SLEDAI-2K 56.5% and 99.2%, respectively. Kappa coefficients of these instruments were 0.902 (95% CI: 0.847, 0.957), 0.870 (95% CI: 0.805, 0.935), 0.832 (95% CI: 0.761, 0.903), and 0.663 (95% CI: 0.557, 0.769), respectively. The number of flare misclassifications was lowest with the SLE-DAS, and highest with the SLEDAI-2K. Conclusion: The SLE-DAS accurately identifies and categorizes flares as mild or moderate/severe. It is feasible and, thus, may help the physicians’ treatment decisions in the clinical practice setting.


  • Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up

    by Rita N Cunha, Liliana Saraiva, Diogo Jesus, Andrea Doria, José P da Silva, Luís S Inês

    Objectives: The treatment target in SLE should be maintained stable by preventing flares. The objectives were to identify predictors of flare in patients attaining lupus low disease activity state (LLDAS), and to assess whether remission with no glucocorticoids is associated with lower risk of flares. Methods: This was a cohort study of SLE patients followed in a referral centre over 3 years. Baseline was the first visit where each patient attained LLDAS. Flares up to 36 months’ follow-up were identified by three instruments: revised Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA) Flare Index (r-SFI), SLEDAI-2000 (SLEDAI-2K) and SLE Disease Activity Score (SLE-DAS). Demographic, clinical and laboratory parameters at baseline were evaluated as predictors of flare, with distinct models for each flare instrument, using survival analysis with univariate followed by multivariate Cox regression. Hazard ratios (HR) were determined with 95% CI. Results: A total of 292 patients fulfilling LLDAS were included. Over follow-up, 28.4%, 24.7% and 13.4% of the patients developed one or more flare, according to r-SFI, SLE-DAS and SLEDAI-2K definitions, respectively. After multivariate analysis, the predictors of SLE-DAS flares were presence of anti-U1-ribonucleoprotein (anti-U1RNP) (HR = 2.16, 95% CI 1.30, 3.59), SLE-DAS score at baseline (HR = 1.27, 95% CI 1.04, 1.54) and immunosuppressants (HR = 2.43, 95% CI 1.43, 4.09). These predictors were equally significant for r-SFI and SLEDAI-2K flares. Remitted patients with no glucocorticoids presented a lower risk of SLE-DAS flares (HR = 0.60, 95% CI 0.37, 0.98). Conclusion: In patients with LLDAS, anti-U1RNP, disease activity scored by SLE-DAS and SLE requiring maintenance immunosuppressants predict higher risk of flare. Remission with no glucocorticoids is associated with lower risk of flares.


  • Reliability assessment of the definition of ultrasound enthesitis in SpA: results of a large, multicentre, international, web-based study

    by Andrea Di Matteo, Edoardo Cipolletta, Giulia Maria Destro Castaniti, Gianluca Smerilli, Carla Airoldi, Sibel Zehra Aydin, Andrea Becciolini, Karina Bonfiglioli, Alessandra Bruns, Greta Carrara, et al.

    Objectives: To investigate the reliability of the OMERACT US Task Force definition of US enthesitis in SpA.Methods: In this web exercise, based on the evaluation of 101 images and 39 clips of the main entheses of the lower limbs, the elementary components included in the OMERACT definition of US enthesitis in SpA (hypoechoic areas, entheseal thickening, power Doppler signal at the enthesis, enthesophytes/calcifications, bone erosions) were assessed by 47 rheumatologists from 37 rheumatology centres in 15 countries. Inter- and intra-observer reliability of the US components of enthesitis was calculated using Light’s kappa, Cohen’s kappa, Prevalence And Bias Adjusted Kappa (PABAK) and their 95% CIs.Results: Bone erosions and power Doppler signal at the enthesis showed the highest overall inter-reliability [Light’s kappa: 0.77 (0.76–0.78), 0.72 (0.71–0.73), respectively; PABAK: 0.86 (0.86–0.87), 0.73 (0.73–0.74), respectively], followed by enthesophytes/calcifications [Light’s kappa: 0.65 (0.64–0.65), PABAK: 0.67 (0.67–0.68)]. This was moderate for entheseal thickening [Light’s kappa: 0.41 (0.41–0.42), PABAK: 0.41 (0.40–0.42)], and fair for hypoechoic areas [Light’s kappa: 0.37 (0.36–0.38); PABAK: 0.37 (0.37–0.38)]. A similar trend was observed in the intra-reliability exercise, although this was characterized by an overall higher degree of reliability for all US elementary components compared with the inter-observer evaluation.Conclusions: The results of this multicentre, international, web-based study show a good reliability of the OMERACT US definition of bone erosions, power Doppler signal at the enthesis and enthesophytes/calcifications. The low reliability of entheseal thickening and hypoechoic areas raises questions about the opportunity to revise the definition of these two major components for the US diagnosis of enthesitis.


  • Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort

    by Helena Assunção, Diogo Jesus, Maddalena Larosa, Carla Henriques, Ana Matos, Véronique Le Guern, Francisco Rubiño, José A P da Silva, Iñigo Rua-Figueroa, Nathalie Costedoat-Chalumeau, et al.

    To derive and validate a definition of low disease activity (LDA) for SLE based on the SLE Disease Activity Score (SLE-DAS), in a real-life multicentre cohort of SLE patients. Derivation was conducted using data from a monocentric cohort of SLE (Portugal), and validation was performed in a multicentre cohort (Italy, France and Spain). The Lupus Low Disease Activity State (LLDAS) was used as comparator. We applied receiver operating characteristics curve analysis against the LLDAS to determine the cut-off of SLE-DAS for LDA using bootstrap methodology. In a second step, we tested a definition of SLE-DAS LDA that included: (i) the statistically derived SLE-DAS upper threshold for LDA and (ii) prednisone dose ≤7.5 mg/day. In the multicentre validation cohort, we assessed the classification performance of this SLE-DAS LDA definition. We included 774 patients, 300 in the derivation and 474 in the validation cohort. In the derivation cohort, the optimal cut-off to identify patients in LLDAS was SLE-DAS ≤2.48, presenting an area under the curve of 0.965 (95% CI 0.935, 0.994). When applied to the multicentre validation cohort, the SLE-DAS LDA definition showed a sensitivity of 97.1% and a specificity of 97.7% for LLDAS and an almost perfect agreement (Cohen’s Kappa = 0.933; P < 0.001). McNemar’s test found no significant differences between the two definitions (P = 0.092). The SLE-DAS LDA is a validated, accurate and easy-to-use definition for classifying SLE patients in LDA state.


  • Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

    by Diogo Jesus, Maddalena Larosa, Carla Henriques, Ana Matos, Margherita Zen, Paulo Tomé, Valter Alves, Nuno Costa, Véronique Le Guern, Luca Iaccarino, et al.

    Objectives There is an unmet need for accurate and user-friendly definitions of systemic lupus erythematosus (SLE) disease activity and remission. We aimed to derive and validate the SLE Disease Activity Score (SLE-DAS) definitions for disease activity categories and clinical remission state. Methods Derivation was conducted at Padova Lupus Clinic (Italy). Validation was prospectively performed at Cochin Lupus Clinic (France) and by post hoc analysis of BLISS-76 trial. At each clinic, an expert classified patients in three categories: remission, mild or moderate/severe activity. The SLE-DAS cut-offs were derived using the receiver operating characteristic curve analysis in Padova cohort; its performance was assessed against expert classification in Cochin cohort and British Isles Lupus Assessment Group (BILAG) index in BLISS-76. Gold standard for clinical remission state was the fulfilment of Definition Of Remission In SLE. A Boolean and an index-based definitions of remission were sustained by chi-square automatic interaction detection algorithm. An SLE-DAS online calculator was developed and tested. Results We included 1190 patients with SLE: 221 in the derivation cohort and 969 in the validation cohorts (150 from Cochin; 819 from BLISS-76). Derived cut-offs were: remission, SLE-DAS ≤2.08; mild activity, 2.087.64. Regarding validation in Cochin cohort, sensitivity and specificity are above 90%, 82% and 95% for remission, mild and moderate/severe activity, respectively. The SLE-DAS Boolean-based and index-based remission showed sensitivity of 100% and specificity above 97%. Conclusion The SLE-DAS is an accurate and easy-to-use tool for defining SLE clinical remission state and disease activity categories, validated against expert assessment and BILAG.